tag:blogger.com,1999:blog-73861391146606584172024-03-05T13:07:25.860+01:00RespirAndalusUn blog desde el sur sobre patología respiratoria para profesionales de atención primariaUnknownnoreply@blogger.comBlogger197125tag:blogger.com,1999:blog-7386139114660658417.post-7210246656261986992016-01-19T21:10:00.002+01:002016-01-19T21:10:35.899+01:00RespiratoryAt@Glance Spanish Archive<a href="http://www.theipcrg.org/display/RespAtAGlanceSpanish/RespiratoryAt@Glance+Spanish+Archive">http://www.theipcrg.org/display/RespAtAGlanceSpanish/RespiratoryAt@Glance+Spanish+Archive</a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-23670487543932283492016-01-19T21:04:00.002+01:002016-01-19T21:04:35.844+01:00Tiotropio : Del handihaler al Respimat <a href="http://bmjopen.bmj.com/content/5/12/e009015.short?rss=1">http://bmjopen.bmj.com/content/5/12/e009015.short?rss=1</a><br />
<br />
<span style="background: rgb(238, 238, 238); border: 0px; color: #333333; font-family: arial, sans-serif; font-size: 12px; font-weight: 700; line-height: 16.8px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">Conclusions</span><span style="background-color: #eeeeee; color: #333333; font-family: arial, sans-serif; font-size: 12px; line-height: 16.8px;"> This analysis indicates that it is safe to switch patients from tiotropium HandiHaler to tiotropium Respimat, and that the efficacy is maintained over the switch.</span>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-79388468589944102472016-01-19T21:01:00.003+01:002016-01-19T21:01:54.475+01:00¿ Por qué mis pacientes rechazan la vacuna de la gripe ?<a href="http://www.statnews.com/2015/12/11/why-patients-refuse-flu-shot/">http://www.statnews.com/2015/12/11/why-patients-refuse-flu-shot/</a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-10859782869389669202016-01-19T20:59:00.002+01:002016-01-19T20:59:47.320+01:00El fonendo, una herramienta del pasado ?<a href="https://www.washingtonpost.com/national/health-science/heart-doctors-are-listening-for-clues-to-the-future-of-their-stethoscopes/2016/01/02/bd73b000-a98d-11e5-8058-480b572b4aae_story.html?postshare=6231451997336349&tid=ss_tw">https://www.washingtonpost.com/national/health-science/heart-doctors-are-listening-for-clues-to-the-future-of-their-stethoscopes/2016/01/02/bd73b000-a98d-11e5-8058-480b572b4aae_story.html?postshare=6231451997336349&tid=ss_tw</a>Unknownnoreply@blogger.com1tag:blogger.com,1999:blog-7386139114660658417.post-2546134397801967182016-01-19T20:57:00.002+01:002016-01-19T20:57:06.376+01:00Lo esencial para un diagnóstico certero de neumonía<a href="http://sapiensmedicus.org/blog/2014/10/06/diagnostico-certero-de-neumonia/?utm_source=ReviveOldPost&utm_medium=social&utm_campaign=ReviveOldPost">http://sapiensmedicus.org/blog/2014/10/06/diagnostico-certero-de-neumonia/?utm_source=ReviveOldPost&utm_medium=social&utm_campaign=ReviveOldPost</a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-28315651803017919112016-01-19T20:35:00.000+01:002016-01-19T20:35:30.161+01:00Lung cancer screening<a href="http://thorax.bmj.com/content/71/2/103.extract">http://thorax.bmj.com/content/71/2/103.extract</a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-28253957163897195142016-01-19T20:33:00.000+01:002016-01-19T20:33:18.313+01:00COPD Navigator , una app de salud para pacientes con enfermedad pulmonar<a href="http://www.imedicalapps.com/2016/01/review-copd-navigator-health-app/">http://www.imedicalapps.com/2016/01/review-copd-navigator-health-app/</a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-61295008376607105682016-01-19T20:30:00.000+01:002016-01-19T20:30:07.872+01:00Semiologia de tipos de respiración: Kussmaul, Cheyne-Stokes, Biot<a href="http://medicinamnemotecnias.blogspot.com/2016/01/semiologia-tipos-de-respiracion.html">http://medicinamnemotecnias.blogspot.com/2016/01/semiologia-tipos-de-respiracion.html</a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-65189441190260284022015-09-28T20:01:00.000+02:002015-09-28T20:01:01.249+02:00Efficacy of a respiratory rehabilitation exercise training package in hospitalized elderly patients with acute exacerbation of COPD: a randomized control trial<br />
<a href="https://www.dovepress.com/efficacy-of-a-respiratory-rehabilitation-exercise-training-package-in--peer-reviewed-article-COPD">https://www.dovepress.com/efficacy-of-a-respiratory-rehabilitation-exercise-training-package-in--peer-reviewed-article-COPD</a><br />
<br />
<br />
<strong style="background: rgb(255, 255, 255); border: 0px; color: #555555; font-family: Verdana, 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 13.125px; line-height: 21px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">Conclusion:</strong><span style="background-color: white; color: #555555; font-family: Verdana, 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 13.125px; line-height: 21px;"> Results of this study suggest that the respiratory rehabilitation exercise training package reduced symptoms and enhanced the effectiveness of the care of elderly inpatients with AECOPD.</span><br />
<br />Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-80356320178176246192015-09-28T19:55:00.002+02:002015-09-28T19:55:49.466+02:00Escuela de pacientes : Taller de fisioterapia respiratoria Parte 2/2<iframe allowfullscreen="" frameborder="0" height="270" src="https://www.youtube.com/embed/NVbvgyhEfpQ" width="480"></iframe>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-77073326655518663852015-09-28T19:55:00.001+02:002015-09-28T19:55:13.554+02:00Escuela de Pacientes : Taller de fisioterapia respiratoria Parte 1/2<iframe allowfullscreen="" frameborder="0" height="270" src="https://www.youtube.com/embed/B2OQnvT6cKQ" width="480"></iframe>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-39426982684569542802015-09-28T19:39:00.005+02:002015-09-28T19:39:46.343+02:00CADIME : Dispositivos de inhalación<a href="http://www.cadime.es/docs/algoritmos/CADIME_ALGORITMO_TTO_EPOC%20ESTABLE-MEDICAMENTOS-DISPOSITIVOS2.pdf">http://www.cadime.es/docs/algoritmos/CADIME_ALGORITMO_TTO_EPOC%20ESTABLE-MEDICAMENTOS-DISPOSITIVOS2.pdf</a><br />
<br />
<br />Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-31378830306974180132015-09-28T19:38:00.002+02:002015-09-28T19:40:07.442+02:00CADIME : ALGORITMO DE TRATAMIENTO FARMACOLÓGICO DE LA EPOC ESTABLE <a href="http://www.cadime.es/docs/algoritmos/CADIME_ALGORITMO_TTO_EPOC%20ESTABLE-MEDICAMENTOS-DISPOSITIVOS2.pdf">http://www.cadime.es/docs/algoritmos/CADIME_ALGORITMO_TTO_EPOC%20ESTABLE-MEDICAMENTOS-DISPOSITIVOS2.pdf</a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-75050612301008268202015-09-17T12:25:00.001+02:002015-09-17T12:25:42.843+02:00Hospitalizaciones potencialmente evitables por descompensación de EPOC<a href="http://www.atlasvpm.org/documents/10157/0e89ca32-b9f5-431c-b7e3-4a09dbc7f05d">http://www.atlasvpm.org/documents/10157/0e89ca32-b9f5-431c-b7e3-4a09dbc7f05d</a><br />
<br />
<div style="text-align: justify;">
Las hospitalizaciones evitables son un indicador indirecto de la capacidad de resolución de la Atención Primaria y directo del
volumen de actividad hospitalaria potencialmente prevenible mediante cuidados oportunos y efectivos en el primer nivel
asistencial. La hipótesis de partida es que, la correcta aplicación de intervenciones habitualmente proporcionadas por Atención
Primaria – prevención primaria, diagnóstico y tratamiento temprano y/o seguimiento y control adecuados-, los cuidados
ambulatorios especializados y la cooperación entre niveles asistenciales supondría una importante reducción de las tasas de
este tipo de hospitalizaciones.
Las hospitalizaciones por descompensación de Enfermedad Pulmonar Obstructiva Crónica (EPOC) están incluidas entre las
“hospitalizaciones potencialmente evitables” y se utilizan como indicador de la calidad y coordinación de la atención a los
pacientes frágiles o con enfermedades crónicas. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<span style="background-color: #e0e0e0; font-family: Arial, Helvetica, Verdana, sans-serif; line-height: 15.4px; text-align: start;"><br /></span></div>
<div style="text-align: justify;">
</div>
<ul>
<li><span style="background-color: #e0e0e0; font-family: Arial, Helvetica, Verdana, sans-serif; line-height: 15.4px; text-align: start;">El Atlas VPM (Variaciones en la Práctica Médica) evalúa la asistencia sanitaria recibida por más de 45 millones de españoles en 203 áreas sanitarias de las 17 Comunidades Autónomas.</span></li>
</ul>
<br />
<div style="text-align: justify;">
<span style="background-color: #e0e0e0; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 11px; line-height: 15.4px; text-align: start;"><br /></span></div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-80653401290978206062015-09-16T21:16:00.001+02:002015-09-16T21:16:44.156+02:00Bromuro de Umeclidinio / Vilanterol. Evaluación del CEVIME<a href="http://www.osakidetza.euskadi.eus/contenidos/informacion/cevime_nuevo_medicamento/es_nme/adjuntos/BROMURO%20DE%20UMECLIDINIO_VILANTEROL_es_def.pdf">http://www.osakidetza.euskadi.eus/contenidos/informacion/cevime_nuevo_medicamento/es_nme/adjuntos/BROMURO%20DE%20UMECLIDINIO_VILANTEROL_es_def.pdf</a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-89062906059214883032015-09-16T21:14:00.000+02:002015-09-16T21:16:51.488+02:00Bromuro de Umeclidinio. Evaluación del CEVIME <a href="http://www.osakidetza.euskadi.eus/contenidos/informacion/cevime_nuevo_medicamento/es_nme/adjuntos/BROMURO%20DE%20UMECLIDINIO_es_def.pdf">http://www.osakidetza.euskadi.eus/contenidos/informacion/cevime_nuevo_medicamento/es_nme/adjuntos/BROMURO%20DE%20UMECLIDINIO_es_def.pdf</a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-21282335981808668192015-09-16T21:08:00.000+02:002015-09-16T21:08:28.777+02:00Controversias en EPOC<a href="http://www.erspublications.com/content/controversies-in-copd">http://www.erspublications.com/content/controversies-in-copd</a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-86590135758126376662015-09-14T17:00:00.002+02:002015-09-14T17:00:51.961+02:00El test CAT en la EPOC. Una revisión sistemática<a href="http://erj.ersjournals.com/content/44/4/873.long">http://erj.ersjournals.com/content/44/4/873.long</a>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-35922202475839988762015-09-14T16:56:00.000+02:002015-09-16T21:09:52.147+02:00Rehabilitación pulmonar en la EPOC. Revisión Cochrane<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003793.pub3/abstract;jsessionid=32195F3C9B2291966B85BD1D567952BD.f01t03">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003793.pub3/abstract;jsessionid=32195F3C9B2291966B85BD1D567952BD.f01t03</a>Unknownnoreply@blogger.com1tag:blogger.com,1999:blog-7386139114660658417.post-29329270402285047202015-08-04T11:02:00.000+02:002015-08-04T11:02:13.455+02:00Recursos de MBE del American Family Physician<a href="http://www.aafp.org/journals/afp/authors/ebm-toolkit/resources.html">http://www.aafp.org/journals/afp/authors/ebm-toolkit/resources.html</a><br />
<br />Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-36745898670700410482015-08-04T10:56:00.001+02:002015-08-04T10:56:21.341+02:00Cómo realizar una espirometría de calidad<a href="https://www.youtube.com/watch?v=6KIPK92OYnE&index=15&list=PLX8gn9E0dsu5j3Jb_rg4nUDOEeUHi2oTF">https://www.youtube.com/watch?v=6KIPK92OYnE&index=15&list=PLX8gn9E0dsu5j3Jb_rg4nUDOEeUHi2oTF</a><br />
<br />
Un video de P2P FEGAS<br />
<br />
<span style="background-color: white; color: #555555; font-family: Roboto, arial, sans-serif; font-size: 13px; line-height: 16.8999996185303px;">"P2P: del Profesional para el Profesional" es un programa formativo de la Fundación Pública Escuela Gallega de Administración Sanitaria (FEGAS) basado en la gestión del conocimiento a través de píldoras formativas que responden a necesidades formativas básicas en el ámbito clínico con contenidos breves y directos. </span>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-2784350667533019752015-08-04T10:53:00.001+02:002015-08-04T10:53:34.038+02:00¿QUÉ ES LA ASMATECA?<a href="http://www.separasma.com/que-es-la-asmateca/">http://www.separasma.com/que-es-la-asmateca/</a><br />
<br />
<br />Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-54214875638648049762015-08-04T10:50:00.003+02:002015-08-04T10:50:52.938+02:00Ejercicio aeróbico y asma<h1 id="article-title-1" itemprop="headline" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; color: #333333; font-family: arial, sans-serif; font-stretch: normal; margin: 15px 0px 2px; outline: 0px; padding: 0px; vertical-align: baseline;">
<span style="font-size: small;">Aerobic training decreases bronchial hyperresponsiveness and systemic inflammation in patients with moderate or severe asthma: a randomised controlled trial</span></h1>
<div>
<span style="font-size: small;"><a href="http://thorax.bmj.com/content/70/8/732.abstract?sid=1e34b5e0-272e-4f8f-af9b-da663a59950e">http://thorax.bmj.com/content/70/8/732.abstract?sid=1e34b5e0-272e-4f8f-af9b-da663a59950e</a></span></div>
<div>
<br /></div>
<div>
<div class="subsection" id="sec-4" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; clear: both; color: #333333; font-family: Arial, sans-serif; line-height: 13px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">
<div id="p-5" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-image-outset: initial; border-image-repeat: initial; border-image-slice: initial; border-image-source: initial; border-image-width: initial; border: 0px; font-family: arial, sans-serif; font-stretch: normal; line-height: 1.4em; margin-bottom: 15px; margin-top: 2px; outline: 0px; padding: 0px; text-align: inherit; vertical-align: baseline;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-image-outset: initial; border-image-repeat: initial; border-image-slice: initial; border-image-source: initial; border-image-width: initial; border: 0px; font-family: inherit; font-style: inherit; font-weight: 700; line-height: inherit; margin: 0px; outline: 0px; padding: 0px; text-align: inherit; vertical-align: baseline;">Conclusions</span> Aerobic training reduced <span style="background-color: #eeeeee; line-height: 16.7999992370605px;">bronchial hyperresponsiveness </span><span style="line-height: 1.4em; text-align: inherit;">and serum proinflammatory cytokines and improved quality of life and asthma exacerbation in patients with moderate or severe asthma. These results suggest that adding exercise as an adjunct therapy to pharmacological treatment could improve the main features of asthma.</span></div>
<div style="font-size: 10px;">
<br /></div>
</div>
<div class="subsection" id="sec-5" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border: 0px; clear: both; color: #333333; font-family: Arial, sans-serif; font-size: 10px; line-height: 13px; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">
</div>
</div>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-2474936741564110702015-08-04T10:47:00.002+02:002015-08-04T10:47:59.686+02:00Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.<a href="http://www.ncbi.nlm.nih.gov/m/pubmed/26208998/?i=5&from=copd">http://www.ncbi.nlm.nih.gov/m/pubmed/26208998/?i=5&from=copd</a><br />
<br />Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-7386139114660658417.post-41877361118328023172015-08-04T10:46:00.000+02:002015-08-04T10:46:20.764+02:00(COCHRANE): En un paciente con asma bien controlado con LABA + Corticoides inhalados ¿se debe suspender el LABA? <br />
<span style="background-color: #f5f8fa; color: #292f33; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 16px; line-height: 22px; white-space: pre-wrap;">(COCHRANE) En un paciente con asma bien controlado con LABA + Corticoide inhalado ¿se debe suspender el LABA? </span><br />
<span style="background-color: #f5f8fa; color: #292f33; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 16px; line-height: 22px; white-space: pre-wrap;"><br /></span>
<span style="background-color: #f5f8fa; line-height: 22px; white-space: pre-wrap;"><span style="color: #292f33; font-family: Helvetica Neue, Helvetica, Arial, sans-serif;">Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids</span></span><br />
<span style="background-color: #f5f8fa; line-height: 22px; white-space: pre-wrap;"><span style="color: #292f33; font-family: Helvetica Neue, Helvetica, Arial, sans-serif;"><br /></span></span>
<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011306.pub2/abstract">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011306.pub2/abstract</a><br />
<br />
<div class="headingCont" style="background: rgb(233, 239, 240); border: 0px; font-family: Arial, 'Lucida Grande', Geneva, Verdana, Helvetica, 'Lucida Sans Unicode', sans-serif; font-size: 10px; line-height: 10px; margin: 1em -0.5em; outline: 0px; padding: 0.3em 0.3em 0px; position: relative; vertical-align: baseline;">
<h2 style="background: transparent; border: 0px; color: #5d5d5d; font-size: 1.2em; margin: 0px 0px 1em; outline: 0px; padding: 0px; vertical-align: baseline;">
Authors' conclusions</h2>
</div>
<div style="background: rgb(255, 255, 255); border: 0px; font-family: Arial, 'Lucida Grande', Geneva, Verdana, Helvetica, 'Lucida Sans Unicode', sans-serif; font-size: 1.2em; line-height: 1.3em; margin-bottom: 1em; outline: 0px; padding: 0px; vertical-align: baseline;">
This review suggests that stopping LABA in adults who have stable asthma while they are taking a combination of LABA and ICS inhalers may increase the likelihood of asthma exacerbations that require treatment with oral corticosteroids, but this is not certain. Stopping LABA may slightly reduce asthma control and quality of life, but evidence was insufficient to show whether this had an effect on important outcomes such as serious adverse events and exacerbations requiring hospital admission, and longer trials are warranted. Trialists should include patient-important outcomes such as asthma control and quality of life and should use validated measurement tools. Definitions of exacerbations should be provided.</div>
<div>
<br /></div>
Unknownnoreply@blogger.com0